Antitumor effect of reduction of 150-kDa oxygen-regulated protein expression on human prostate cancer cells

Tohru Miyagi1, Osamu Hori, Kiyoshi Koshida

  • 1Department of Urology, Kanazawa University School of Medicine, Kanazawa, Japan.

Abstract

Insights

Antisense ORP150 cDNA delivered via adenovirus reduced prostate cancer growth by suppressing VEGF secretion. This gene therapy approach shows promise for reducing tumor formation and angiogenicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Oxygen-regulated protein 150 (ORP150), a heat shock protein and molecular chaperone, is upregulated in infiltrating prostate cancer cells.
  • Enhanced expression of ORP150 and vascular endothelial growth factor (VEGF) is observed in human prostate cancer.
  • ORP150's role in promoting cancer progression warrants investigation for therapeutic targeting.

Purpose of the Study:

  • To investigate if antisense ORP150 cDNA can suppress VEGF secretion, thereby reducing prostate cancer's angiogenicity and tumorigenicity.
  • To evaluate the efficacy of adenoviral-mediated gene transfer of antisense ORP150 cDNA in prostate cancer models.

Main Methods:

  • Immunohistochemical analysis of ORP150 and VEGF in prostate cancer specimens.
  • Adenovirus vector carrying antisense ORP150 cDNA (AdCA-Antisense ORP150) for transduction of DU145 prostate cancer cells.
  • Western blotting for ORP150 expression, ELISA for VEGF secretion, chorioallantoic membrane (CAM) assay for angiogenicity, and nude mouse xenograft model for tumorigenicity.

Main Results:

  • Adenovirus vector demonstrated 100% transduction efficiency with minimal cytotoxicity.
  • Antisense ORP150 cDNA significantly reduced ORP150 expression and suppressed VEGF secretion by 30%.
  • Reduced angiogenicity in CAM assays and marked suppression of tumor formation in xenograft models were observed.

Conclusions:

  • Adenoviral-mediated transfer of antisense ORP150 cDNA effectively inhibits prostate cancer growth and angiogenesis.
  • This gene therapy strategy targeting ORP150 and VEGF suppression holds potential for prostate cancer treatment.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...